Back to top
more

Humana (HUM)

(Real Time Quote from BATS)

$355.19 USD

355.19
650,230

+8.04 (2.32%)

Updated May 16, 2024 12:36 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (48 out of 250)

Industry: Medical - HMOs

Better trading starts here.

Zacks News

Humana (HUM) Outpaces Stock Market Gains: What You Should Know

Humana (HUM) closed at $472.50 in the latest trading session, marking a +0.73% move from the prior day.

The Zacks Analyst Blog Highlights Humana, Cintas, Biogen, Royal Caribbean Cruises and Markel Group

Humana, Cintas, Biogen, Royal Caribbean Cruises and Markel Group are part of the Zacks top Analyst Blog.

Humana (HUM) Gains As Market Dips: What You Should Know

In the latest trading session, Humana (HUM) closed at $471.98, marking a +1.49% move from the previous day.

Mark Vickery headshot

Top Analyst Reports for Humana, Cintas & Biogen

Today's Research Daily features new research reports on 16 major stocks, including Humana Inc. (HUM), Cintas Corporation (CTAS) and Biogen Inc. (BIIB).

Humana (HUM) Down 5.2% Since Last Earnings Report: Can It Rebound?

Humana (HUM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why Investors Should Hold Humana (HUM) in Portfolio

Humana (HUM) remains well-poised for growth on the back of an expanding Medicare Advantage membership, upgraded health plan offering suite and solid cash reserves.

Humana (HUM) to Provide In-home Care With Primary Care Anywhere

Humana (HUM) enhances its CenterWell brand with the launch of Primary Care Anywhere.

Why Humana (HUM) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Debasmita Chatterjee headshot

5 HMO Stocks to Watch Amid Growing Premiums & Membership

Expanding customer base, contract wins and a rapidly growing aging U.S. population will likely drive the performances of the Zacks Medical-HMO industry players. UNH, CI, HUM, CNC and MOH are poised to benefit from favorable industry trends.

Humana (HUM) to Bring Enhanced Kidney Care to MA Members

Humana (HUM) makes Interwell's extensive resources available to its MA members grappling with CKD and ESKD, and hence bring about better health outcomes for them.

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Encompass Health's (EHC) Q2 Earnings Beat, '23 EPS View Raised

Encompass Health's (EHC) Q2 results reflect a growing patient base and improved net patient revenue per discharge. Management anticipates 2023 adjusted EPS within $3.31-$3.53, up from the earlier view of $2.94-$3.23.

Company News for Aug 3, 2023

Companies in The News Are: VRTX, DVN, AFL, HUM

Humana (HUM) Q2 Earnings Beat on Strong Individual MA Unit

Humana's (HUM) Q2 results gain from strong pharmacy revenues and revenue growth within the Insurance segment, partly offset by higher benefits expenses.

Private Sector Jobs Come in Higher Than Expected

Private Sector Jobs Come in Higher Than Expected.

Mark Vickery headshot

ADP Jobs +324K Still Higher than Expected; CVS, KHC, HUM Report

ADP Chief Economist Nela Richardson said, "The economy is doing better than expected... we continue to see a slowdown in pay growth without broad-based job loss."

Humana (HUM) Reports Q2 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Humana (HUM) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Humana (HUM) Surpasses Q2 Earnings Estimates

Humana (HUM) delivered earnings and revenue surprises of 0.68% and 0.34%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Will Humana (HUM) Q2 Earnings Beat on Strong Pharmacy Business?

Humana's (HUM) second-quarter results are likely to reflect rising premiums and investment income.

Aparajita Dutta headshot

5 Low-Leverage Stocks to Buy Following the Fed Rate Hike

The crux of safe investment lies in choosing a company that is not burdened with debt, as a debt-free stock is almost impossible to find. You may buy HUM, TEX, ARI, ATO and TNK.

Centene (CNC) Q2 Earnings and Revenues Surpass Estimates

Centene (CNC) delivered earnings and revenue surprises of 2.44% and 3.44%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Molina (MOH) Q2 Earnings Beat on High Premiums, '23 View Raised

Molina Healthcare's (MOH) second-quarter results are aided by increased membership, and Medicaid and Medicare strength.

Humana (HUM) Earnings Expected to Grow: Should You Buy?

Humana (HUM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Humana (HUM) Gains But Lags Market: What You Should Know

In the latest trading session, Humana (HUM) closed at $454.34, marking a +0.2% move from the previous day.

Here's What to Expect From Acadia Healthcare's (ACHC) Q2 Earnings

Acadia Healthcare's (ACHC) Q2 results are likely to reflect increased patient volumes across its U.S. operations, partly offset by a higher expense base.